Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Clin J Am Soc Nephrol. 2013 May;8(5):797-803. doi: 10.2215/CJN.10000912. Epub 2013 Jan 31.
The optimal dialysate calcium concentration to maintain normal mineralization and reduce risk of cardiovascular events in hemodialysis patients is debated. Guidelines suggest that dialysate Ca concentration should be lowered to avoid vascular calcification, but cardiac arrhythmias may be more likely to occur at lower dialysate Ca. Concurrent use of QT-prolonging medications may also exacerbate arrhythmic risk. This study examined the influence of serum Ca, dialysate Ca, and QT interval-prolonging medications on the risk of sudden cardiac arrest in a cohort of hemodialysis patients.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This case-control study among 43,200 hemodialysis patients occurred between 2002 and 2005; 510 patients who experienced a witnessed sudden cardiac arrest were compared with 1560 matched controls. This study examined covariate-adjusted sudden cardiac arrest risk associations with serum Ca, dialysate Ca, serum dialysate Ca gradient, and prescription of QT-prolonging medications using logistic regression techniques.
Patients assigned to low Ca dialysate<2.5 mEq/L were more likely to be exposed to larger serum dialysate Ca gradient and had a greater fall in BP during dialysis treatment. After accounting for covariates and baseline differences, low Ca dialysate<2.5 mEq/L (odds ratio=2.00, 95% confidence interval=1.40-2.90), higher corrected serum Ca (odds ratio=1.10, 95% confidence interval=1.00-1.30), and increasing serum dialysate Ca gradient (odds ratio=1.40, 95% confidence interval=1.10-1.80) were associated with increased risk of sudden cardiac arrest, whereas there were no significant risk associations with QT-prolonging medications.
Increased risk of sudden cardiac arrest associated with low Ca dialysate and large serum dialysate Ca gradients should be considered in determining the optimal dialysate Ca prescription.
为了维持血液透析患者的正常矿化并降低心血管事件的风险,最佳透析液钙浓度仍存在争议。指南建议降低透析液 Ca 浓度以避免血管钙化,但较低的透析液 Ca 可能更易导致心律失常。同时使用延长 QT 间期的药物也可能会增加心律失常的风险。本研究在一组血液透析患者中,研究了血清 Ca、透析液 Ca 和延长 QT 间期的药物对心搏骤停风险的影响。
设计、地点、参与者和测量方法:这项在 2002 年至 2005 年间进行的 43200 例血液透析患者的病例对照研究中,510 例发生目击心搏骤停的患者与 1560 例匹配对照进行了比较。本研究使用逻辑回归技术,研究了血清 Ca、透析液 Ca、血清-透析液 Ca 梯度和延长 QT 间期药物处方与校正后心搏骤停风险的相关性。
接受低钙透析液<2.5 mEq/L 的患者更可能暴露于较大的血清-透析液 Ca 梯度,并在透析治疗期间血压下降更大。在考虑了协变量和基线差异后,低钙透析液<2.5 mEq/L(比值比=2.00,95%置信区间=1.40-2.90)、较高的校正血清 Ca(比值比=1.10,95%置信区间=1.00-1.30)和增加的血清-透析液 Ca 梯度(比值比=1.40,95%置信区间=1.10-1.80)与心搏骤停风险增加相关,而与延长 QT 间期的药物无显著风险相关性。
低钙透析液和较大的血清-透析液 Ca 梯度与心搏骤停风险增加相关,在确定最佳透析液 Ca 处方时应予以考虑。